BioSenic S.A. : Transparency notifications received from François Rieger
PRESS RELEASE – REGULATED INFORMATION
See the original post here:
BioSenic S.A. : Transparency notifications received from François Rieger
Author Archives: admin
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic…
PRESS RELEASE – INSIDE INFORMATION
Read the original:
BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic...
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
Pratteln, Switzerland, January 15, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age and older, irrespective of the underlying mutation and ambulatory status, in Germany.
See more here:
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy
Basilea announces acquisition of preclinical antibiotics program from Spexis
Allschwil, Switzerland, January 15, 2024
The rest is here:
Basilea announces acquisition of preclinical antibiotics program from Spexis
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
VANCOUVER, Canada, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) is proud to introduce Sirona LaboratoriesTM - a wholly-owned subsidiary dedicated to maximizing the commercial potential of its breakthrough anti-aging skincare ingredient, GlycoProteMimTM.
View post:
Sirona Biochem Launches Cosmetics Subsidiary- Sirona Laboratories™
XORTX Announces $2 Million Public Offering
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES
Original post:
XORTX Announces $2 Million Public Offering
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19 Can provide protection for millions of immuno-compromised and elderly who are most vulnerable to COVID-19
Read the original post:
ExeVir Bio Announces Positive Virus Neutralization Data for XVR012 Against Emerging COVID-19 Omicron Variants
Guerbet: Financial agenda for 2024
Financial agenda for 2024
Originally posted here:
Guerbet: Financial agenda for 2024
GENFIT Announces 2024 Financial Calendar
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its provisional financial calendar for 2024.
Read more from the original source:
GENFIT Announces 2024 Financial Calendar